SEATTLE and VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its second quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Thursday, August 7, 2025, at 8:30 AM EDT. To access the webcast, ...

Squeaky-Clean Singapore Steps Up Crackdown on Vapes https://t.co/oHn1Xs7C8b ...

The Food and Drug Administration is allowing Juul, the brand widely blamed for sparking the teen vaping trend, to keep its ecigarettes on the market. That decision, announced late last week, concludes a multi-year review that left the products in limbo. Juel is celebrating the move, but others are criticizing it, including Democratic Senator Dick Durban of Illinois, who claims the company ignited a youth vaping epidemic and is calling on FDA Commissioner Dr.. Marty McCary to reverse the decision. Dr.. McCar ...

The risks of vaping may be worth the benefits https://t.co/HuHu1KZ7vu ...

Meet The Startup That Makes Quitting Cigarettes, Vaping And Zyn Cool https://t.co/sQaZRlsAGm https://t.co/sQaZRlsAGm ...

Core Insights - VOOPOO showcased its latest technologies and products at the World Vape Show Dubai 2025, earning significant attention and accolades, including two prestigious awards at the Vapouround Global Awards 2025 [1][9] Group 1: Awards and Recognition - VOOPOO received the "Industry Leader" award, recognizing its relentless pursuit of innovation and influential role in shaping the vaping industry [4][5] - The PnP X Pod Tank won the "Best Tank MTL" title, further solidifying VOOPOO's commitment to quality and user experience [5] Group 2: Technological Innovations - VOOPOO's iCOSM CODE 2.0 technology offers 30-day cleanness, steady flavor, and 100 mL e-liquid endurance, showcasing the company's commitment to advancing vaping technology [6] - The ARGUS series, featuring products like the ARGUS G3 and ARGUS Klyc, integrates the iCOSM 2.0 technology, providing users with consistent flavor and ease of use [7] Group 3: Upcoming Products - VOOPOO previewed upcoming products such as the ARGUS Matrix, which features a curved full screen and cyber-futuristic visuals, and the VMATE Pro 2, known for its extended battery life and smart interactive features [8] Group 4: Market Position - The recognition through professional media awards reaffirms VOOPOO's position as a global leader in vaping technology, pushing boundaries to deliver smarter and more immersive experiences [9]

Core Viewpoint - Achieve Life Sciences, Inc. is conducting a public offering of 15 million shares of common stock and accompanying warrants at a price of $3.00 per share, aiming to raise approximately $45 million to support the development of cytisinicline for nicotine dependence treatment [1][4]. Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline as a treatment for nicotine dependence and smoking cessation [7]. - The company submitted a New Drug Application to the FDA for cytisinicline in June 2025, based on successful Phase 3 studies and an open-label safety study [7]. Offering Details - The public offering includes 15 million shares and warrants, with an additional 2.25 million shares available for underwriters to purchase [1][3]. - Each common warrant can be exercised for common stock at $3.00 or for pre-funded warrants at $2.999, expiring five years from issuance [2]. Financial Aspects - The gross proceeds from the offering are expected to be around $45 million, which will be used for advancing cytisinicline towards FDA approval and for general corporate purposes [4]. - The offering is expected to close around June 30, 2025, pending customary closing conditions [3]. Market Context - There are approximately 29 million adult smokers in the U.S., with tobacco use being the leading cause of preventable death [8]. - Cytisinicline has been granted Breakthrough Therapy designation by the FDA to address the need for effective treatments for nicotine e-cigarette cessation, as there are currently no FDA-approved options for this indication [9].

Core Insights - Airis has launched its latest flagship product, the NEO P40000, which aims to redefine user experience in the vaping industry with advanced features and technology [1][2] Product Features - The NEO P40000 offers up to 40,000 puffs due to its high-capacity battery and efficient e-liquid storage, providing convenience for daily use and travel [2][6] - It incorporates a triple-core structure for enhanced flavor delivery, ensuring even heat conduction and faster vaporization for a more authentic taste [2][5] - A smart chip integrated into the device allows real-time monitoring of battery level, e-liquid remaining, and nicotine strength, enhancing user trust and efficiency [2][4] - The device features a five-level nicotine adjustment, allowing users to customize their vaping experience based on personal needs [3][4] - A high-precision puff monitoring system tracks usage frequency, aiding users in managing their intake and supporting smoking cessation goals [4][6] - The NEO P40000 includes a three-level airflow adjustment slider, enabling users to customize draw resistance according to their preferences [5][6] - It offers 20 custom flavors developed by Airis' flavor team, providing a diverse and enjoyable flavor experience [5][6] User Value and Feedback - The device is designed for various scenarios, including daily commuting, long-distance travel, and stress relief, making it versatile for users [6] - User feedback highlights the convenience of the device, consistent flavor delivery, and practical features like battery and e-liquid level displays [6] Brand Commitment and Future Outlook - Airis is committed to continuous innovation and improvement in user experience, focusing on safety and quality to lead in the smart vaping market [6][7] - The launch of the NEO P40000 marks a significant milestone for Airis as it aims to establish itself as a trusted leader in the global vaping industry [7]

Group 1 - CEA Industries Inc. will change its ticker symbol from "CEAD" to "VAPE" on the NASDAQ Capital Market, effective June 13, 2025 [1] - The new ticker symbol "VAPE" reflects the company's strategic focus on the growing vaping industry, particularly after acquiring Fat Panda, a leading Canadian vape retailer [2] - The change in ticker symbolizes the company's commitment to the regulated vape sector and aims to enhance visibility and positioning with investors and customers [3] Group 2 - CEA Industries is focused on building category-leading businesses in regulated consumer markets, particularly in the high-growth Canadian nicotine vape industry [4] - The company targets scalable operators with strong regulatory alignment and high-margin business models, providing capital and operational expertise to accelerate retail expansion [4]

Company Overview - Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence and smoking cessation [3] - The company has successfully completed two Phase 3 studies and one Phase 2 study related to cytisinicline for smoking and vaping cessation [3] - Achieve plans to submit its new drug application for smoking cessation in June 2025 and has conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication [3] Product Information - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors in the brain, helping to reduce nicotine cravings and the satisfaction associated with nicotine products [6] - Approximately 29 million adults in the U.S. smoke combustible cigarettes, and tobacco use is the leading cause of preventable death, responsible for over eight million deaths worldwide annually [4] - There are over 11 million adults in the U.S. who use e-cigarettes, with no FDA-approved treatments specifically for nicotine e-cigarette cessation, highlighting a critical need that cytisinicline aims to address [5] Upcoming Events - Rick Stewart, CEO of Achieve, will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 5:30 PM EDT, with a live webcast available on the company's Investor Relations website [2]